Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, Asiri Ediriwickrema et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29
Data from The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and <i>TET2</i>-Mutant PreleukemiaYusuke Nakauchi, Ravindra Majeti, Armon Azizi et al.|Unknown|2023Cited by 0
Data from The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and <i>TET2</i>-Mutant PreleukemiaYusuke Nakauchi, Ravindra Majeti, Armon Azizi et al.|Unknown|2023Cited by 0
Supplementary Figure from The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and <i>TET2</i>-Mutant PreleukemiaYusuke Nakauchi, Ravindra Majeti, Armon Azizi et al.|Unknown|2023Cited by 0
Supplementary Table from The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and <i>TET2</i>-Mutant PreleukemiaYusuke Nakauchi, Ravindra Majeti, Armon Azizi et al.|Unknown|2023Cited by 0